David Ross, MD, PhD, Royal Adelaide Hospital, Adelaide, Australia, discusses quality of life (QoL) for patients with polycythemia vera and essential thrombocythemia, commenting on the chronic nature of these diseases resulting in a need for prolonged treatment and highlighting the limited trials investigating the targeting of specific symptoms in this population. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

свернуть